Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surlorian in Adults With Autosomal Dominant RYR1-Related Myopathy
NCT07560020Phase 2Recruiting
- Sponsor
- RyCarma Therapeutics
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of Surlorian in RYR1-related myopathy (RYR1-RM), sponsored by RyCarma Therapeutics. Started Sep 2026; status: recruiting.
02
Drugs
Surlorian
03
Conditions
RYR1-related myopathy (RYR1-RM)
Beyond the preview
Go deeper on NCT07560020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560020.